Multiple Myeloma
In November 2021, the FDA approved the combination of subcutaneous Darzalex Faspro (daratumumab and hyaluronidase) plus Kyprolis (carfilzomib) and dexamethasone for adults with relapsed or refractory multiple myeloma who have received previous therapy. Read More ›
Nurse practitioner Beth Faiman, PhD, MSN, an expert in multiple myeloma, briefly discusses the unique features of this uncurable but very treatable cancer, highlighting that getting what you want out of treatment requires arming yourself with knowledge about the disease, evaluating your treatment goals, familiarizing yourself with your treatment team, and becoming an active participant in your treatment. Read More ›
This publication was created together with leading patient advocates who shared their experiences and insights, in the hope that it will help you connect with patient organizations and resources as you and your care partners navigate through your diagnosis and treatment. These patient organizations provide education and support to promote your health and well-being, and help with practical matters, logistics, and financial and legal concerns. Read More ›
James D. Bond describes his crucial experience in a clinical trial and thanks the devoted care of his wife Kathleen and the medical team for his continued success in battling this deadly blood cancer. Read More ›
This special issue was developed together with leading patient advocates, who shared their experiences and insight, with the hope that it will help you connect with patient organizations and resources as you and your care partners navigate through your diagnosis and treatment. These organizations provide education and support for your health and well-being, as well as help with practical matters, logistics, and financial and legal concerns. Read More ›
In July 2021, the FDA approved a new indication for Darzalex Faspro (daratumumab and hyaluronidase-fihj), for use in combination with Pomalyst (pomalidomide) and dexamethasone, for adults with multiple myeloma who have received at least 1 previous line of therapy. Read More ›
In March 2021, the FDA approved a new indication for Sarclisa (isatuximab-irfc), in combination with Kyprolis and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma. Read More ›
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute. Read More ›